Company intelligence / Profile preview

SANUWAVE Health

Ownership: Public · SNWV
Employees: ~50
Development stage: Commercial

Overview

SANUWAVE’s lead product dermaPACE® is FDA-cleared for diabetic foot ulcers following successful Phase III trials showing efficacy over standard of care. The UltraMIST® system is also FDA-approved with nationwide CMS reimbursement. Clinical data support improved healing rates in chronic wounds using these noninvasive energy-based therapies.

Therapeutic areas: EndocrinologyDermatologyRheumatologyCardiovascularNeurology
Modalities: DeviceNon-pharmacological therapyBiologic
Industry: Biotech

Drug pipeline

2 assets

UltraMIST System

Commercial

Indications: Wound healing

1 more asset in the full pipeline.

Request access →

Partnerships

Celularity Inc.

Financials

Market cap: $34.4M
Total revenue: $9.7M
Enterprise value: $45.7M

Beyond the preview

Go deeper on SANUWAVE Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SANUWAVE Health.

Explore the full profile